Comparative Pharmacology
Head-to-head clinical analysis: ANGIOVIST 282 versus ANGIOVIST 292.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOVIST 282 versus ANGIOVIST 292.
ANGIOVIST 282 vs ANGIOVIST 292
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiovist 282 (diatrizoate meglumine and diatrizoate sodium) is a radiographic contrast agent that contains iodine, which attenuates X-rays, allowing visualization of vascular structures and organs. It increases the contrast between blood vessels and surrounding tissues by absorbing X-rays.
Angiovist 292 (diatrizoate meglumine and diatrizoate sodium) is an ionic, high-osmolar iodinated contrast agent. It functions by absorbing x-rays due to the high atomic number of iodine, thereby enhancing the radiopacity of vascular structures and organs during diagnostic imaging. It also increases the osmolarity of the intravascular compartment, which can lead to hemodynamic effects.
Iohexol (ANGIOVIST 282) is a nonionic iodinated contrast medium. Typical adult dose: 50-200 mL intravenously or intra-arterially, depending on procedure (e.g., CT: 75-150 mL IV).
Intravenous administration: 50-150 mL of a 292 mg iodine/mL solution for adults, depending on the imaging procedure, with a maximum total dose of 300 mL per procedure.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; prolonged to >30 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion via glomerular filtration; unchanged drug: >95% within 24 hours. Biliary/fecal: <5%.
Primarily renal; >90% of dose excreted unchanged in urine within 24 hours. Fecal excretion is negligible (<1%).
Category C
Category C
Contrast Agent
Contrast Agent